ReviewWorld journal of hepatology2015
Review on immunosuppression in liver transplantation.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- Oral diseases after liver transplantation: a systematic review and meta-analysis.British dental journal · 2021Pooled it
- Reporting patterns of renal failure associated with immunosuppressant combinations following liver transplantation: a retrospective analysis.Clinical transplantation and research · 2026Article
- Administration of human macrophage colony-stimulating factor-mFc fusion protein increases macrophage phagocytic capacity and stimulates liver regeneration in mice.Journal of inflammation (London, England) · 2026Article
- Review
- Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis.World journal of hepatology · 2026Article
- Effects of tacrolimus treatment on the gut microbiota and metabolites in liver transplant recipients.PloS one · 2026Article
- Liver transplantation in patients with history of extra-hepatic malignancies.Frontiers in transplantation · 2026Article
- Macrophage Actin Cytoskeleton in Chronic Rejection.Results and problems in cell differentiation · 2026Review
- Convergence of Several Biorhythms in Immunosuppressive Therapy for Liver Transplantation: Commentary on Ushijima et al.Clinical pharmacology and therapeutics · 2025Article
- Complications Associated with Immunosuppressive Agents in Solid Organ Transplant Recipients: A Nationwide Analysis.Journal of clinical medicine · 2025Article
- Side Effects of Immunosuppressant Drugs After Liver Transplant.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Characterizing the Use of Prolonged-Release Once-Daily Tacrolimus (LCPT) across Canada.The Canadian journal of hospital pharmacy · 2025Article
- Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier.Hepatology international · 2024Review
- Current Management of Neuroendocrine Tumour Liver Metastases.Current oncology reports · 2024Review
- Comparison of the effect of Everolimus, Prednisolone, and a combination of both on experimentally induced peritoneal adhesions in rats.Scientific reports · 2024Article
- Article
- Immunology demystified: A guide for transplant hepatologists.World journal of transplantation · 2024Review
- Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape.Diagnostics (Basel, Switzerland) · 2024Review
- Life-Threatening Electrical Storm Following Liver Transplantation: A Case Report.The American journal of case reports · 2024Article
- The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: a potential solution to an unmet medical need.Frontiers in immunology · 2024Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal level of immunosuppression in solid organ transplantation, in particular for the liver, is a delicate balance between the benefit of preventing rejection and the adverse side effects of immunosuppression. There is uncertainty about when this level is achieved in any individual recipient. Immunosuppression regimens vary between individual centers and changes with time as new agents and data are available. Presently concerns about the adverse side effects of calcineurin inhibitor, the main class of immunosuppressive agents used in liver transplantation (LT), has led to consideration of the use of antibody induction therapies for patients at higher risk of developing adverse side effects. The longevity of the transplanted organ is potentially improved by better management of rejection episodes and special consideration for tailoring of immunosuppression to the individual with viral hepatitis C, hepatocellular carcinoma or pregnancy. This review provides an overview of the current strategies for post LT immunosuppression and discusses modifications to consider for special patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.